Literature DB >> 31046090

Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients.

Sérgio Barra1,2,3, Rudolf Duehmke4, Rui Providência5, Kumar Narayanan6,7, Christian Reitan8, Tomas Roubicek9, Rostislav Polasek9, Antony Chow5, Pascal Defaye10, Laurent Fauchier11,12, Olivier Piot13, Jean-Claude Deharo14, Nicolas Sadoul15, Didier Klug16, Rodrigue Garcia17, Seth Dockrill3, Munmohan Virdee3, Stephen Pettit3, Sharad Agarwal3, Rasmus Borgquist8, Eloi Marijon7,18,19, Serge Boveda20.   

Abstract

AIMS: The very long-term outcome of patients who survive the first few years after receiving cardiac resynchronization therapy (CRT) has not been well described thus far. We aimed to provide long-term outcomes, especially with regard to the occurrence of sudden cardiac death (SCD), in CRT patients without (CRT-P) and with defibrillator (CRT-D). METHODS AND
RESULTS: A total of 1775 patients, with ischaemic or non-ischaemic dilated cardiomyopathy, who were alive 5 years after CRT implantation, were enrolled in this multicentre European observational cohort study. Overall long-term mortality rates and specific causes of death were assessed, with a focus on late SCD. Over a mean follow-up of 30 months (interquartile range 10-42 months) beyond the first 5 years, we observed 473 deaths. The annual age-standardized mortality rates of CRT-D and CRT-P patients were 40.4 [95% confidence interval (CI) 35.3-45.5] and 97.2 (95% CI 85.5-109.9) per 1000 patient-years, respectively. The adjusted hazard ratio (HR) for all-cause mortality was 0.99 (95% CI 0.79-1.22). Twenty-nine patients in total died of late SCD (14 with CRT-P, 15 with CRT-D), corresponding to 6.1% of all causes of death in both device groups. Specific annual SCD rates were 8.5 and 5.8 per 1000 patient-years in CRT-P and CRT-D patients, respectively, with no significant difference between groups (adjusted HR 1.0, 95% CI 0.45-2.44). Death due to progressive heart failure represented the principal cause of death (42.8% in CRT-P patients and 52.6% among CRT-D recipients), whereas approximately one-third of deaths in both device groups were due to non-cardiovascular death.
CONCLUSION: In this first description of very long-term outcomes among CRT recipients, progressive heart failure death still represented the most frequent cause of death in patients surviving the first 5 years after CRT implant. In contrast, SCD represents a very low proportion of late mortality irrespective of the presence of a defibrillator. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac resynchronization therapy; Cause of death; Heart failure; Implantable cardioverter-defibrillator; Sudden cardiac death

Year:  2019        PMID: 31046090     DOI: 10.1093/eurheartj/ehz238

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  The year in cardiology: heart failure.

Authors:  John G F Cleland; Alexander R Lyon; Theresa McDonagh; John J V McMurray
Journal:  Eur Heart J       Date:  2020-03-21       Impact factor: 29.983

2.  Trends in the use of implantable cardioverter-defibrillator and cardiac resynchronization therapy device in advancing age: Analysis of the Japan cardiac device treatment registry database.

Authors:  Hisashi Yokoshiki; Akihiko Shimizu; Takeshi Mitsuhashi; Kohei Ishibashi; Tomoyuki Kabutoya; Yasuhiro Yoshiga; Ritsuko Kohno; Haruhiko Abe; Akihiko Nogami
Journal:  J Arrhythm       Date:  2020-06-08

3.  What Cannot Be Missed: Important Publications on Electrophysiology in 2019.

Authors:  Andrew Grace; Hugh Calkins; Ken Ellenbogen; Pier D Lambiase; Gregory Yh Lip; Sanjiv M Narayan; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2020-06-03

4.  Shortening of time-to-peak left ventricular pressure rise (Td) in cardiac resynchronization therapy.

Authors:  Hans Henrik Odland; Manuel Villegas-Martinez; Stian Ross; Torbjørn Holm; Richard Cornelussen; Espen W Remme; Erik Kongsgard
Journal:  ESC Heart Fail       Date:  2021-09-12

5.  Mortality among ischemic and nonischemic heart failure patients with a primary implantable cardioverter-defibrillator.

Authors:  Pil-Sung Yang; Younghyun Kang; Han-Joon Bae; Jung-Hoon Sung; Hyung-Deuk Park; Boyoung Joung
Journal:  J Arrhythm       Date:  2021-10-29

6.  Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project.

Authors:  Moritz Hadwiger; Nikolaos Dagres; Janina Haug; Michael Wolf; Ursula Marschall; Jan Tijssen; Alexander Katalinic; Fabian Simon Frielitz; Gerhard Hindricks
Journal:  Eur Heart J       Date:  2022-07-14       Impact factor: 35.855

7.  A long-term cost-effectiveness analysis of cardiac resynchronisation therapy with or without defibrillator based on health claims data.

Authors:  Moritz Hadwiger; Laura Schumann; Nora Eisemann; Nikolaos Dagres; Gerhard Hindricks; Janina Haug; Michael Wolf; Ursula Marschall; Alexander Katalinic; Fabian-Simon Frielitz
Journal:  Cost Eff Resour Alloc       Date:  2022-09-02

8.  CHA2DS2-VASc Score and the Risk of Ventricular Tachyarrhythmic Events and Mortality in MADIT-CRT.

Authors:  Eyal Nof; Valentina Kutyifa; Scott McNitt; Jeffrey Goldberger; David Huang; Mehmet K Aktas; Rosero Spencer; Ilan Goldenberg; Roy Beinart
Journal:  J Am Heart Assoc       Date:  2019-12-31       Impact factor: 5.501

9.  Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator.

Authors:  Moritz Hadwiger; Fabian-Simon Frielitz; Nora Eisemann; Christian Elsner; Nikolaos Dagres; Gerhard Hindricks; Alexander Katalinic
Journal:  Appl Health Econ Health Policy       Date:  2021-01       Impact factor: 2.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.